Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders

Generalized Anxiety Disorder Clinical Trial

Official title:

Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03585010
• Other study ID #: 2000023649
• Secondary ID: 4R33MH115113-031
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 1, 2018
• Est. completion date: March 31, 2024

Study information

• Verified date: February 2024
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to investigate whether a parent-based treatment for childhood anxiety disorders engages child brain circuitry implicated in children's reliance on parents to reduce anxiety (R61), and whether change in child brain circuitry is associated with reduction in child anxiety (R33).

Description:

Specific Aims: Anxiety disorders impact up to one-third of children, cause tremendous suffering, increase risk for psychiatric and medical morbidity, impair school and social functioning, and cost billions of dollars each year. Data consistently show that child anxiety is characterized by amygdala hyperactivity and deficits in prefrontal control of the amygdala. Emerging data link these disruptions to anxious children's over-reliance on parents for amygdala-medial prefrontal cortex (mPFC) engagement and anxiety reduction. In the first phase of this study we aim to demonstrate that an entirely parent-based psychosocial treatment with no child involvement, Supportive Parenting for Anxious Childhood Emotions (SPACE), engages an amygdala-mPFC target in anxious children, lessening child reliance on parents to reduce amygdala reactivity. Cross-species neurobiological evidence indicates that parental presence reduces amygdala reactivity and activates the mPFC to reduce offspring anxiety. In humans we recently demonstrated parental presence increases functional connectivity between their child's mPFC and amygdala, reducing the child's amygdala reactivity and anxiety. In a healthy sample, parental engagement of child amygdala-mPFC connectivity was linked to the child's reliance on parents for help with anxiety. Data from clinically anxious children likewise show parental presence engages child mPFC, and data we collected since our previous submission demonstrate that parental presence reduces amygdala reactivity in clinically anxious children. Offspring's natural reliance on parents for anxiety reduction is magnified in clinically anxious children. Parents become deeply enmeshed in their child's symptoms through the process of family accommodation, defined as change in parents' behavior to help the child avoid or alleviate anxiety. In clinically anxious children, 90% report depending on parents to reduce their anxiety, and 97% of parents report accommodating their anxious child's symptoms. These cross-generational patterns of parental entanglement in their child's anxiety symptoms contribute to the immense burden, distress, and costs of pediatric anxiety (e.g., parents missing work to be with their anxious child). Anxious children's reliance on parents for anxiety reduction may disrupt the child's ability to independently reduce amygdala reactivity and anxiety. We developed SPACE to translate these neurobiological and clinical research findings into a manualized parent-based treatment focused on reducing family accommodation in parents of anxious children. Preliminary data from a randomized clinical trial show that after 12 weeks of parents receiving SPACE (N=29), with no therapist-child contact, family accommodation and child anxiety were significantly reduced. We propose that SPACE engages anxious children's amygdala-mPFC circuitry, lessening their reliance on parents to reduce amygdala reactivity. The first phase of the study will examine clinically anxious children's (N=90, 7-10 yrs) amygdala-mPFC response to fear faces when (A) the child's parent is beside them holding their hand during the fMRI scan (Parent-Present), and (B) the child is alone during the scan (Parent-Absent) (within-subjects design). Children with primary separation, social, or generalized anxiety disorder diagnoses, the most common childhood anxiety disorders, will serve as participants. Children will complete Parent-Present and Parent-Absent scans PRE- and POST-SPACE, or PRE- and POST-Parent Educational Support (PES), the comparator treatment that controls for treatment duration and therapist-parent contact. We expect SPACE will lessen child reliance on parental presence to engage amygdala-mPFC circuitry and reduce child amygdala reactivity. Aim 1: Demonstrate SPACE lessens children's reliance on parents to reduce amygdala reactivity (target engagement). Hyp 1: Child reliance on parental presence to reduce amygdala reactivity, (i.e., the difference between child amygdala reactivity in the Parent-Present and Parent-Absent scan), will decrease significantly from PRE- to POST-SPACE, as compared with PRE- to POST-PES. If Hyp 1 is confirmed we will proceed to the the second phase of the study. The second phase of the study will be performed to re-demonstrate target engagement in SPACE, compared to cognitive-behavioral therapy (CBT); demonstrate target engagement is associated with symptom reduction in SPACE; and demonstrate SPACE's acceptability/feasibility. The second phase will enroll 136 clinically anxious children (7-10 yrs), randomly assigned to SPACE or CBT. Aim 1: Re-demonstrate target engagement in SPACE. Hyp 1: Child reliance on parental presence to reduce amygdala reactivity will decrease significantly from PRE- to POST-SPACE, as compared with PRE- to POST-CBT. Aim 2: Demonstrate target engagement is associated with symptom reduction in SPACE. Hyp 2: Reduction in child anxiety from PRE- to POST-SPACE will be significantly associated with reduction in child reliance on parental presence to reduce amygdala reactivity. Aim 3: Establish acceptability and feasibility of SPACE. Hyp 3: SPACE will be acceptable and feasible to administer, and comparable to CBT. The second phase will also provide insight into the relative efficacy of SPACE, to inform future research and development of SPACE. This study has the potential to provide groundbreaking results, with major public health impact, on how parent-based treatments can target disrupted neurobiological processes in children with psychopathology. These novel data will inform decision-making about a large-scale study (R01) to confirm the efficacy of SPACE and examine personalized treatment strategies.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 226
• Est. completion date: March 31, 2024
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years to 12 Years

Eligibility

Inclusion Criteria:

• Prepubertal
• Clinical diagnosis of primary anxiety disorder
• Must not have another mental illness more impairing than the most impairing anxiety disorder
• IQ of at least 80.

Exclusion Criteria:

• Neurological disorders (including seizures)
• Organic mental disorders, psychotic disorders, or pervasive developmental disorders
• High likelihood of hurting themselves or others
• Current psychosocial or psychopharmacological treatment
• History of neurological illness or head injury with loss of consciousness > 5 minutes
• Vision or physical disability that interferes with seeing stimuli presented briefly on computer screen and/or clicking a mouse button rapidly and repeatedly
• Contraindications for MRI scanning (e.g., metal implants, pacemakers, braces, claustrophobia, pregnancy, weight > 250 pounds).

Related Conditions & MeSH terms

• Anxiety Disorder of Childhood
• Anxiety Disorders
• Anxiety, Separation
• Generalized Anxiety Disorder
• Phobia, Social
• Separation Anxiety Disorder of Childhood
• Social Anxiety Disorder of Childhood

Intervention

Behavioral:
• Supportive Parenting for Anxious Childhood Emotions
12 sessions with parents
• Parent Educational Support
12 sessions with parents
• Cognitive-Behavioral Therapy
12 sessions with child

Locations

Country	Name	City	State
United States	Yale University Child Study Center	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pediatric Anxiety Rating Scale (PARS)	The PARS is a clinician-administered measure of anxiety severity in children and adolescents.; Total scores on PARS are used as indicator of anxiety severity. Total scores range from 0-35, with higher scores indicating more severe anxiety.	12 weeks
Secondary	Multimodal Anxiety Scale for Children (MASC)	The MASC is a self-report measure of anxiety severity, completed by children and parents separately.; MASC generates a total anxiety score and several sub scales: Total scores: range from 0-150 Separation/Phobias scores: range from 0-27 Generalized anxiety scores: range from 0-30 Social anxiety scores: range from 0-27 Obsessive-compulsive symptom scores: 0-50 Physical symptoms scores: 0-60 For Total score and all sub-scales, higher scores indicate more severe anxiety.	12 weeks